# NIH Guide
## for Grants and Contracts

U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES

Vol. 14, No. 10, September 13, 1985

SPECIAL EDITION

**********

IMPORTANT NOTICE INSIDE

RESPONSE REQUIRED

The mailing lists for the NIH Guide for Grants and Contracts and the NIH Guide Supplements are being purged. Please see the Notice on page 1 and the response form on page 37.

**NOTE THAT A RESPONSE IS REQUIRED IF YOU WISH TO RECEIVE NOTICES OF RESEARCH OPPORTUNITIES FROM THE NATIONAL INSTITUTES OF HEALTH.** See page 1 for details.

**********

The NIH Guide is published at irregular intervals to announce scientific initiatives and to provide policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in grants and contracts activities administered by the National Institutes of Health.

Two types of supplements are published by the respective awarding units. Those printed on yellow paper concern contracts: solicitations of sources and announcement of availability of requests for proposals. Those printed on blue paper concern invitations for grant applications in well-defined scientific areas to accomplish specific program purposes.

**Have You Moved?**
If you present address differs from that shown on the address label, please send your new address to: Grants and Contract Guide Distribution Center, National Institutes of Health, Room B3BN10, Building 31, Bethesda, Maryland 20205, and attach your address label to your letter. Prompt notice of your change of address will prevent your name from being removed from our mailing list.

# I N D E X

Vol. 14, No. 10, September 13, 1985

IN THIS ISSUE:

# NOTICE TO ALL RECIPIENTS OF NIH GUIDE FOR GRANTS AND CONTRACTS AND GUIDE SUPPLEMENTS

**P.T. 04, 12, 18, 22, 24, 34, 36, 42, 44; K.W. 0710030, 072005, 0780000, 1014002**

NIH is sending this combined issue of the NIH Guide for Grants and Contracts to all recipients of the NIH Guide and Guide Supplements for the purposes of announcing major changes in the publication and distribution of these documents and purging the mailing keys. Currently the NIH announces its research interests in two principal ways. The NIH Guide For Grants and Contracts, published approximately every four weeks, includes policy and informational notices affecting grants and contracts and solicitations for assistance (grant and cooperative agreement) programs. It is published by the Office of Extramural Research and Training (OERT), a component of the Office of the Director, NIH, and is sent to a mailing list of approximately 23,000 individuals and institutional representatives. The NIH Guide also contains selected research announcements from other agencies of the Public Health Service (PHS) and occasionally other Federal agencies. Recipients of this publication receive all announcements related to assistance programs, although the specialized Requests for Applications (RFAs) are published in abbreviated form with the full text available on request.

Guide Supplements are sent to individuals and institutional officials who have indicated an interest in receiving notices of availability of Requests for Proposals (RFPs) related to projects to be funded by the contract mechanism. Supplements also announce requests for organizations to provide statements of their capabilities to perform certain types of research or research-related activities (Sources Sought Announcements). Supplement recipients indicate their interest in receiving RFP notices in one or more scientific areas. Supplements are published by individual awarding components following review by OERT. The average Supplement goes to 12,000 individuals, some of whom receive the NIH Guide as well.

NIH staff have been exploring ways to reduce the costs of publishing these documents while maintaining or improving the quality and timeliness of the information provided to the research community. Previous efforts have focused on ways to refine further the various mailing keys in order to target announcements more specifically to individual scientists' research interests. It has become apparent, however, that this approach is clearly less cost-effective because of the substantial per-page costs associated with the individual Supplement mailings. It also carries the disadvantage of possibly excluding individuals who may have an interest in responding to a particular announcement. Therefore the NIH has decided to combine the Guide and Supplements into a single publication that will be published once a week and mailed to interested individuals and offices.

As a first step, mailing lists for the Guide and Supplements will be combined in a dataset that will be matched against responses to the purge notice included as a tear-off sheet at the end of this issue. **IF YOU WISH TO CONTINUE TO RECEIVE NOTICES OF RESEARCH OPPORTUNITIES (REGARDLESS OF FUNDING MECHANISM OR AWARDING COMPONENT), YOU MUST COMPLETE AND RETURN THE FORM THAT APPEARS ON THE LAST PAGE OF THIS ISSUE.**

Recipients of the NIH Guide will not experience a major change. The publication will appear more frequently and will include notices of availability of RFPs in addition to the program announcements, RFA notices, and policy notices you have been receiving in the past. Recipients who have been receiving Supplements in

one or more categories on an intermittent basis will now receive a weekly publication including program opportunities and policy notices for NIH as a whole, as well as selected research announcements from other agencies of the PHS. The format of the index will be designed to facilitate quick identification of announcements that are time-limited or of special interest to a particular field of research.

Although this change will result in more people receiving more undifferentiated information, the cost savings will be substantial. It will also be more in keeping with the recent removal of most legislative and policy restrictions limiting eligibility for various mechanisms to certain categories of applicants.

The new weekly NIH Guide for Grants and Contracts will be mailed by third-class mail to all who indicate their interest by returning the form included in this special issue. NIH has used third-class mail for the monthly publication for some time with no major delays. However, prospective contract offerors who depend on the Guide for timely notification of the availability of RFPs should be advised that these notices will henceforth be mailed third-class and only once a week. You may wish to subscribe to the Commerce Business Daily if you prefer to have access to such notices as soon as they are released.

The Commerce Business Daily is available by subscription for $160.00/year (first-class) or $81.00/year (second class). A six month trial subscription may be obtained for $88.00 (first class) or $45.00 (second class).

To order, send a purchase order and a check made out to the Superintendent of Documents (Visa and Mastercard accepted) to the following address:

Superintendent of Documents
Government Printing Office
Washington, D.C. 20402

Telephone: (202) 783-3238

Contract proposal solicitation notices will also carry a numerical code that will be new to some readers. Since February 1984, NIH has participated with several other Federal research agencies in the Keyword Thesaurus Project. The codes identify each announcement by "program type" and "Key Word" to facilitate matching of announcement subject matter with the interests of individual readers. After completion of the mailing purge, a list of Thesaurus terms relevant to NIH programs will be included in a future issue, as well as information on how to obtain the Thesaurus.

After the new publication system is well established, NIH plans to convert to some type of computerized on-line access to a database that is easily accessible to individuals and institutions through remote terminals, e.g., personal computer and modem. Printed copies will be made available on a very limited basis for institutional business offices and individuals who have no other access. This additional change will not take place until the weekly schedule is well established, a method of access has been developed, and appropriate instructions have been provided.

## NOTICE

### Change in Application Receipt Dates

### Effective Date: January 1, 1986

**P.T. 04, 22,34,44; K.W. 0710030, 0404000**

The Division of Research Grants (DRG) NIH, receives applications for research and training grants and cooperative agreements for the Public Health Service (PHS). More than 30,000 competing applications are processed and assigned for review and funding each year.

Competing applications are received on a cycle linked to the meeting times of the initial review groups and the National Advisory Councils and Boards that review the applications. One of DRG's major responsibilities is to analyze application trends with a view toward making the best use of limited resources by distributing workloads as evenly as possible within the constraints of a cyclical review process. As a result of this analysis, DRG has established new receipt dates. These dates appear on the following page.

Please note these dates are effective January 1, 1986.

# APPLICATION RECEIPT DATES, REVIEW AND AWARD SCHEDULE

| Application Receipt Dates | | | | Initial Review Group Dates | National Advisory Council/ Board Dates | Earliest Possible Beginning Date * |
|---|---|---|---|---|---|---|
| Jan. 10<br>May 10<br>Sept. 10<br><br>for<br><br>All individual NRSA applications.*<br>All new and competing continuation Institutional NRSA Training grant applications. | Feb. 1<br>June 1<br>Oct. 1<br><br>for<br><br>All new research grant applications, unless specified differently in a Program Announcement or Request for Applications.<br>Career Development awards and Conference grant applications.<br>New and competing continuation Program Project and Center applications. | Mar. 1<br>July 1<br>Nov. 1<br><br>for<br><br>Competing continuation & supplemental research grant applications. | Apr. 15<br>Aug. 15<br>Dec. 15<br><br>for<br><br>Small Business Innovation (SBIR) Program, both Phases. (Phase II applicants must have completed a federally-funded Phase I project.) | May/June<br>Oct./Nov.<br>Feb./Mar. | Sept./Oct.<br>Jan./Feb.<br>May/June | Dec. 1<br>Apr. 1<br>July 1 |

* Individual NRSA applications are not reviewed by Council. Their start dates are therefore approximately 4 months earlier than indicated.

All applications must be received by the above dates. If the receipt date falls on a weekend, it will be extended to Monday; if the date falls on a holiday, it will be extended to the following workday. The receipt date will be waived only in extenuating circumstances. To request such a waiver, include an explanatory letter with the signed completed application. No waiver will be granted prior to receipt of the application. It is in an applicant's best interest to submit early and avoid the otherwise unavoidable rush associated with announced receipt dates.

effective January 1, 1986

## NOTICE

## RECEIPT AND REFERRAL OF APPLICATIONS

**P.T. 04, 22, 34, 44; K.W. 0710030, 0404000**

**DIVISION OF RESEARCH GRANTS**

Reminders and Clarifications

The Division of Research Grants (DRG) is the central receipt point for all research and training grant applications and all cooperative agreement applications submitted to the Public Health Service (PHS) for funding consideration. Annually, more than 30,000 competing applications are processed and assigned by the DRG Referral Section to PHS review Committees and funding components.

The following information is provided to applicants to help ensure that their applications will move speedily and smoothly through this heavily trafficked system with less likelihood of being returned or delayed on procedural grounds.

1. Receipt Dates

   - Applications are to be received on or before the receipt date. If the receipt date falls on a weekend, it will be extended to Monday; if the date falls on a national holiday, it will be extended to the following work day.

   - The Referral Section maintains a first-in first-out system of processing applications. Hence, it is very much in an applicant's best interest to submit early and avoid the otherwise unavoidable rush associated with announced receipt dates.

   - Requests for waiver of receipt dates are considered only after all applications that have arrived by the receipt date have been processed. To request such a waiver, applicants must include an explanatory letter with the signed completed application. The letter (not under separate cover) should describe the extenuating circumstances that would justify special treatment. No waiver can be granted prior to receipt of the application.

2. Personal Data on Principal Investigator/Program Director

   - Grant Application Form PHS 398 contains a page for providing personal data. The principal investigator/program director is requested to complete the form and attach a single copy to the original signed face page of the application. Additional copies of this form should **NOT** be attached to the duplicated copies of the application.

- o Upon receipt of the application by the Referral Section, this form will be separated from the original application to which it has been attached. It will **NOT** be duplicated and it will **NOT** be a part of the review process. Its sole use, as noted in the application kit, is to facilitate monitoring of real or apparent inequities in PHS programs related to age, sex, race, or ethnicity of the proposed principal investigator/program director (in aggregate terms only).

3. Page Numbers

   - o Pages should be numbered consecutively with Arabic numerals, e.g., 5, 6, 7, 8, 9, 10,.... Do not use lettered page numbers, i.e., 5a, 5b, 5c.

4. Title of Application

   - o Do not exceed 56 typewriter spaces. Longer titles will be truncated by computer or may be edited by someone unfamiliar with the subject matter. In either case, the revised title may not convey the meaning intended by its author.

5. Correspondence

   - o Applicants who wish to provide information intended to facilitate the assignment and review of their applications should do so by attaching a cover letter to the application at the time of submission. Letters sent under separate cover before or after submission run the risk of never getting matched up with the correct application.

   - o Applicants wishing to make corrections in their applications or provide additional materials for review should wait until they receive the post card informing them of the Initial Review Group assignment. Then they should communicate directly with that office. If the post card has not been received within five weeks after the submission date, contact the Referral Section (301) 496-7447.

6. Revised Applications

   - o When a revised application is submitted, it must contain a statement explaining the changes--additions, deletions, and responses to criticisms in the previous summary statement. Revised applications will be returned by the Referral Section if no substantial revisions have been made or if the nature of the revision is not entirely clear.

## NOTICE

### WORKSHOP SERIES - CARE AND USE OF LABORATORY ANIMALS

**P.T. 42; K.W. 0201011, 1014003**

**OFFICE FOR PROTECTION FROM RESEARCH RISKS**

The National Institutes of Health (NIH), Office for Protection from Research Risks (OPRR) is continuing to sponsor a series of workshops on implementing the revised "Public Health Service Policy on the Humane Care and Use of Laboratory Animals by Awardee Institutions" and the NIH Guide for the Care and Use of Laboratory Animals. The workshops are open to institutional administrators, animal care committee members, laboratory animal veterinarians, investigators, and others who share in responsibility for sound management of humane animal research. The current schedule includes:

| Date | Location | Contact |
|---|---|---|
| Oct. 21-22, 1985 | Dallas, TX | Mrs. Edith McGain<br>Univ. of Texas Hlth Sci. Ctr<br>5323 Harry Hines Blvd.<br>Dallas, TX 75235<br>(214)688-3340 |
| March 12, 1986 | Little Rock, AR | Ms. Kathleen Masterson<br>Univ. of Arkansas Med. Ctr.<br>4301 W. Markham<br>Mail Slot 636<br>Little Rock, AR 77205<br>(501) 661-5502 |
| April 4, 1986 | Boston, MA | Mrs. Virginia B. Werwath<br>Harvard Medical Sch., NERPRC<br>One Pine Hill Drive<br>Southborough, MA 01772<br>(617) 481-0400 Ext 202 |

Additional workshops will be announced later. For further information regarding education programs contact:

Roberta H. Garfinkle
Education Program Coordinator
Office for Protection from Research Risks
National Institutes of Health
Building 31 - Room 4B09
9000 Rockville Pike
Bethesda, Maryland 20892

## NOTICE

## EXTENDED APPLICATION RECEIPT DATE

AVAILABILITY OF REQUEST FOR APPLICATIONS: RFA

COOPERATIVE AGREEMENTS FOR NATIONAL COLLABORATIVE

CHEMOPREVENTION PROJECTS

85-CA-15

P.T. 34; K.W. 0715035, 0745055, 0760035

NATIONAL CANCER INSTITUTE

The application receipt date for the above listed announcement published in the NIH Guide for Grants and Contracts, Vol. 14, No. 9, July 18, 1985, has been extended. The new application receipt date is **November 15, 1985.**

## ERRATUM

## ANNOUNCEMENT

MULTIDISCIPLINARY RESEARCH CENTER(S) FOR THE STUDY OF NEURO-GENETIC DISORDERS OF INFANCY AND CHILDHOOD

P.T. 04; K.W. 0705055, 1002019, 0715135,0785165, 0403020, 0770005, 0755030, 0745020, 0415000

NATIONAL INSTITUTE OF NEUROLOGICAL AND COMMUNICATIVE DISORDERS AND STROKE

In Vol. 14, No. 9, July 18, 1985 issue of the NIH Guide for Grants and Contracts, an incomplete telephone number was entered for the above-mentioned announcement. On page 20 under "APPLICATION PROCEDURE" the correct telephone number should be as follows:

496-6515

## NOTICE

## BIOLOGICAL SPECIMENS FOR AIDS-RELATED RESEARCH

**P.T. 36; K.W. 0780005**

**NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES**

**NATIONAL CANCER INSTITUTE**

The National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute (NCI) have developed a repository of biological specimens from homosexual men. The specimens were collected through contracts with five major U.S. universities for studies of the natural history of acquired immune deficiency syndrome (AIDS). Information about applying for collaborative use of these specimens and pertinent epidemiological data is now available from the Project Officer. For further information, write to:

Project Officer
AIDS Repository
Epidemiology and Biometry Section
National Institute of Allergy and
Infectious Diseases
Westwood Building - Room 739
National Institutes of Health
Bethesda, Maryland 20892

## NOTICE

## CHANGE IN ZIP CODES

Effective immediately, the zip code for most components of the National Institutes of Health is 20892. The new zip code for the National Library of Medicine is 20894.

## ANNOUNCEMENT

## MINORITY HIGH SCHOOL STUDENT RESEARCH APPRENTICE PROGRAM

**P.T. 44, FF; K.W. 0720005**

**DIVISION OF RESEARCH RESOURCES**

Application Receipt Date: December 1, 1985

I. BACKGROUND AND OBJECTIVES

The Division of Research Resources (DRR), National Institutes of Health (NIH) currently plans to continue the Minority High School Student Research Apprentice Program in 1986.

The purpose of the program is to provide minority high school students with a meaningful experience in various aspects of health-related research in order to stimulate their interest in careers in science.

II. ELIGIBILITY

Eligible institutions are those that were awarded grants during the latest complete Federal fiscal year 1985 from either the Biomedical Research Support Grant (BRSG) Program or the Minority Biomedical Research Support (MBRS) Program, both of which are administered by DRR, NIH. Only one application for the Apprentice Program can be submitted by an institution that is the recipient of both the BRSG and MBRS awards.

Students selected by the applicant institution that are eligible for support under this program are those who (1) identify themselves as minority (i.e., Black, Hispanic, American Indian, Alaskan native, Pacific Islander, or Asian); (2) are U.S. citizens or have a permanent visa; and (3) were enrolled in high school during the 1985-86 academic year. (Students who will graduate from high school in 1986 are eligible, as is a student who participated in a previous year - provided he/she is still enrolled at the high school level.)

III. MECHANISM OF SUPPORT

The mechanism of support for this program will be the NIH grant-in-aid. Support will be provided at a level of $1,500 for each apprentice position allocated. No indirect costs will be paid. Direct support to the apprentice must be as salary; stipends are not allowed. Within the $1,500 per student allocation, funds may also be utilized for supplies, extending the research experience, or if adequate funds exist, for the addition of an apprentice. However, funds from these grants may only be used for the costs of the apprentice program. The Program Director is responsible for recruitment and selection of the apprentices and assignment of each to an investigator. Recruitment and selection of students should emphasize factors of the students' motivation, ability and scholastic aptitude and accomplishments. In addition, consideration should be given to science teachers' recommendations and where possible the degree of parental commitment. Socioeconomic factors should

be of secondary consideration. Assignments should be made to investigators involved in health-related research who are committed to developing in the high school students both understanding of the research in which they participate and the technical skills needed.

IV. APPLICATION

Eligible institutions should submit an application consisting of no more than:

A. A one page letter stating the number of student positions you are requesting, plus

B. An original and three signed and completed copies of the Grant Application Form, PHS 398 (Rev. 05/82) face page only.

Mark items numbered 4,5, 7, 10 and 14 Not applicable (N.A.). Complete item 8 with the total dollar amount of your request, which is the sum of the number of student positions requested times $1,500 per student.

A progress report and a Financial Status Report will be required by May 31, 1987. Please Note: Limited funds and increased requests for such students positions may restrict the final allocations by DRR to three or four students per eligible applicant institution. Upon recommendation of the National Advisory Research Resources Council, the Division will give preference in making awards to those institutions that can support a summer program having a "critical mass" of at least five or six students using institutional as well as DRR funds.

The applications should be submitted to:

Biomedical Research Support Program
Division of Research Resources
National Institutes of Health
Building 31 - Room 5B-23
9000 Rockville Pike
Bethesda, Maryland 20892

Inquiries can be made of Dr. Thomas G. Bowery, at the above indicated address or by calling (301) 496-6743.

The firm deadline for receipt of applications is December 1, 1985. Awards will be effective March 1, 1986, contingent upon availability of appropriated funds.

## ANNOUNCEMENT

**AVAILABILITY OF REQUEST FOR APPLICATIONS: RFA**

**85-CA-20**

**BASIC STUDIES ON THE DEVELOPMENT AND ASSESSMENT OF RETROVIRAL VACCINES**

**P.T. 34; K.W. 0740075, 10020445, 0710070, 0760080, 0715125, 0755020**

**NATIONAL CANCER INSTITUTE**

**NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES**

Application Receipt Date: December 13, 1985

The Division of Cancer Etiology (DCE), National Cancer Institute (NCI), and the National Institute of Allergy and Infectious Diseases (NIAID), invite applications to conduct grant supported investigator-initiated research on the development and assessment of vaccines against retroviruses.

I. BACKGROUND INFORMATION

Recent research conducted with diverse viruses such as hepatitis B virus, herpes simplex viruses, and foot and mouth disease virus demonstrates that modern approaches in vaccine technology such as packaging of genes coding for immunogenic protective proteins into appropriate expression vectors (such as vaccinia virus) and other recombinant DNA methods can be exploited to produce safe and effective vaccine preparations against the respective viruses. Similar modern approaches need to be explored for the prevention of equally important and devasting diseases caused by retroviruses.

II. OBJECTIVE AND SCOPE

The objective of the RFA is to encourage investigator-initiated research on retroviral vaccines in various laboratories and to emphasize and address those aspects of research presently in need of research stimulation through grant

This program is described in the Catalog of Federal Domestic Assistance 13.394, Cancer Detection and Diagnosis Research and 13.856, Microbiology and Infectious Diseases Research. Grants will be awarded under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended: 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

support. This RFA emphasizing basic studies on the development and assessment of retroviral vaccines invites grant supported studies in the following specific areas, but not necessarily limited to these areas: (1) development of naturally-occurring retrovirus animal models to systematically evaluate strategies for immunogen preparation, vaccination schedules, use of suitable adjuvants, determination of host target cells, induction of a protective immune response, and development of an appropriate measure for in vivo protection against challenge; (2) basic studies to determine how retroviruses interact with and/or escape from the host immune surveillance system, such as by genetic recombination/antigenic shifts/drifts involving env gene alterations; (3) characterization of retroviral components presumed to be immunosuppressive; (4) identification and characterization of antigenic determinants of retroviruses that are most associated with eliciting group and interspecies-specific protective immunity and studies on methodologies to enhance their presentation and immunogenicity; (5) utilization of newer methodologies to produce and evaluate retroviral vaccines such as a) recombinant/subunit vaccines prepared in yeast, bacteria, and/or mammalian cells, b) DNA sequence derived synthetic peptides, c) modified live recombinant DNA retroviral vaccines, d) retroviral gene segment expression vectors such as vaccinia and adenovirus, and e) anti-idiotype antibodies against retroviral components employed as immunizing antigens; and (6) investigations to develop quantitative serological procedures to assess the in vivo immune status against retrovirus infections.

## III. MECHANISM OF SUPPORT

Applications funded in response to this RFA will be supported as research project grants. Responsibility for the planning, direction, and execution of the proposed research will be solely that of the applicant. The total project period for applications submitted in response to the present RFA should not exceed five years. Approximately $2,000,000 ($1,250,00 from NCI and $750,000 from NIAID) will be set aside to specifically fund applications which are submitted in response to this RFA. It is anticipated that twelve to fifteen applications will be funded. This funding level is dependent on the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of the National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Diseases (NIAID), the award of grants pursuant to this RFA is also contingent upon the availability of funds for this purpose. Non-profit and for-profit institutions within the United States may apply. All applications submitted in response to this announcement will be classified as new grants (Type 1). Future competitive renewal applications of grants funded under this RFA will compete with all other unsolicited applications received by the NCI and NIAID. PHS grant policies governing regular research project grants, including cost sharing, apply to applications received in response to this request.

## IV. INQUIRIES

Inquiries and requests for a copy of the RFA may be directed to:

Padman S. Sarma, D.V.M., Ph.D.
Biological Carcinogenesis Branch
National Cancer Institute
Landow Building - Room 9A22
Bethesda, Maryland 20892

Telephone: (301) 496-9734

or

Harry W. Haverkos, M.D.
Microbiology & Infectious Diseases Program
National Institute of Allergy and
Infectious Diseases
Building 31 - Room 7A49
Bethesda, Maryland 20892

Telephone: (301) 496-5893

## ANNOUNCEMENT

## AVAILABILITY OF REQUEST FOR APPLICATIONS: RFA 85-CA-21

## STUDIES ON NOVEL HUMAN EXOGENOUS AND ENDOGENOUS RETROVIRUSES

**P.T. 34; K.W. 1002045, 0755035, 0780020, 0755045, 1002008, 0760015, 0760020**

**NATIONAL CANCER INSTITUTE**

Application Receipt Date: December 13, 1985

The Division of Cancer Etiology (DCE) of the National Cancer Institute (NCI) invites grant applications to perform investigator-initiated basic research to uncover the existence of, and/or characterize novel exogenous and endogenous human retroviruses.

I. BACKGROUND INFORMATION

Recent evidence based on morphologic, molecular biologic and immunologic studies, suggests the existence of hitherto uncharacterized retrovirus particles and endogenous retroviral sequences in human cells. Virus particles with type-C morphology, have been found in human placenta and in certain cell lines derived from human testicular tumors such as embryonal carcinoma and teratocarcinoma. The endogenous retroviruses present in proviral form in human cells are expressed at both messenger RNA and protein levels in certain human tissues. The true nature of these retroviral entities and their role in human cancer need to be determined.

II. OBJECTIVE AND SCOPE

The objective of this RFA is to encourage investigator-initiated basic research to characterize the multiple uncharacterized type-C virus particles and endogenous human retroviruses and determine their significance in human cancer. This RFA emphasizing basic studies on such novel exogenous and endogenous human

This program is described in the Catalog of Federal Domestic Assistance 13.394, Cancer Detection and Diagnosis Research. Grants will be awarded under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended: 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

retroviruses invites grant supported studies in the following specific areas, but not necessarily limited to these areas: (1) molecularly clone the genome(s) of "type-C virions" found in human placenta and tumor tissues (e.g., germ cell tumors) and determine the molecular and antigenic relatedness between these entities and endogenous retroviral sequences found in human cells; (2) identify and characterize protein and nucleic acid components of uncharacterized "type-C virions" by modern technology, and perform studies on viral origin, distribution, and expression in different types of human or other species' tissues. The cells of interest, for example, are germ cells, cells representing different types of germ cell tumors, and differentiating populations of embryonal carcinoma cells; (3) insert cloned human proviral DNA into appropriate expression vectors to study various viral proteins, to determine antigenic composition and relatedness to other retroviruses; (4) search human tumor tissues for viral RNA and protein expression using molecular and immunologic probes derived from novel human retroviral sequences (LTR, and structural regions) and from well-conserved regions of known mammalian retroviruses; (5) develop tissue culture methodologies suitable for cultivation of "difficult to grow" human tumor cells that may have an infectious etiology such as Hodgkin's disease, breast cancer, and B cell lymphomas, using growth factors, special nutrients, and newer specialized cell growth technologies; and (6) isolate and characterize new retroviruses from nonhuman primates with tumors, other diseases, or no disease at all, with a view to using these newer isolates as probes to search for human counterparts.

## III. MECHANISM OF SUPPORT

The support mechanism will be the research project grant. Responsibility for the planning, direction, and execution of the proposed research will be solely that of the applicant. The total project period for applications submitted in response to the present RFA should not exceed five years. Approximately $750,000 will be set aside to specifically fund applications which are submitted in response to this RFA. It is anticipated that five or six applications will be funded. The anticipated starting date is July 1, 1986. This funding level is dependent on the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of the National Cancer Institute (NCI), the award of grants pursuant to this RFA is also contingent upon the availability of funds for this purpose. Non-profit and for-profit institutions may apply. All applications submitted in response to this announcement will be classified as new grants (Type 1). Future competitive renewal applications of grants funded under this RFA will compete with all other unsolicited applications received by the NCI. PHS grant policies governing regular research project grants, including cost sharing, apply to applications received in response to this request.

## IV. INQUIRIES

A copy of the complete RFA describing the research goals and scope, the review criteria and the method of applying can be obtained by contacting:

Padman S. Sarma, D.V.M., Ph.D.
Biological Carcinogenesis Branch
Division of Cancer Etiology
National Cancer Etiology
Landow Building - Room 9A22
Bethesda, Maryland 20892

Telephone: (301) 496-9734

## ANNOUNCEMENT

## SMALL GRANTS PROGRAM FOR RESEARCH ON INHERITED METABOLIC DISEASES

**P.T. 34; K.W. 0715135, 1002004, 1002008, 1002058, 0765035**

**NATIONAL INSTITUTE OF ARTHRITIS, DIABETES, AND DIGESTIVE AND KIDNEY DISEASES**

Application Receipt Date: January 2, 1986

I. INTRODUCTION

The Metabolic Diseases Research Program (Division of Diabetes, Endocrinology and Metabolic Diseases) supports basic research relevant to understanding the molecular and cellular mechanisms of inherited metabolic diseases with the objective of developing efficient treatment modalities and ultimately cure of these disorders. In response to needs identified at a recent workshop, the Program encourages submission of short applications for small grants to fund innovative and/or high risk studies to further understanding of the pathophysiology, molecular biology and genetics of inherited metabolic diseases, including cystic fibrosis.

II. OBJECTIVES AND SCOPE

This program has two distinct objectives.

A. To stimulate experienced investigators to undertake innovative, high risk research, when the successful outcome of such research would rapidly advance the following research areas:

- o Studies of the molecular and cellular mechanisms responsible for abnormal metabolism, including the identification of the biochemical defect, its genetic origin and potential methods for its correction.
- o Development of more efficient and rapid approaches to chromosomal localization of genes associated with inherited metabolic diseases.
- o Development of techniques for homologous recombination between an incoming gene and its counterpart in the mammalian host genome.

This program is described in the Catalog of Federal Domestic Assistance No. 13.847, Diabetes, Endocrinology, and Metabolic Diseases. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended, 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

Diseases of interest include:

- o cystic fibrosis
- o organic and aminoacidurias (including urea cycle disorders)
- o disorders of purine and pyrimidine metabolism
- o storage diseases (e.g., glycogen, mucopolysaccharide, lipid, etc.)

B. To stimulate experienced investigators not currently working in cystic fibrosis to assess the applicability of their work to cystic fibrosis:

Proposals are encouraged for pilot projects to determine the relevance of ongoing investigations in cellular or molecular biology, to understanding the basis of cystic fibrosis. It is emphasized that the lack of present knowledge of the pathophysiologic, molecular and genetic basis of cystic fibrosis renders fundamental investigations in a number of areas suitable for this program.

It is expected that by supporting such meritorious Small Grant applications, understanding of the molecular basis of inherited metabolic diseases will be advanced and new approaches will ultimately be developed for the treatment of some inherited metabolic diseases. In particular, significant progress will be made toward practical use of somatic cell gene transfer.

## III. ELIGIBILITY

A. Independent, established researchers, who are Principal Investigators of at least one active research grant award (R01), or Project Directors of an active component of a program project grant (P01) from any NIH bureau, institute, or division may submit a small grant application in response to this solicitation.

B. Submission of an application under this announcement precludes concurrent submission of a regular research grant application containing the same research proposal. In addition, small grant research support may not be used to supplement research projects currently supported by Federal or non-Federal funds, or to provide interim support of projects under review by the Public Health Service.

C. If the applicant proposes research which will constitute a doctoral dissertation for a graduate student (other than the Principal Investigator), a written statement from the dissertation chairperson or equivalent academic supervisor, that the proposed project has their approval, must accompany the application. If the proposal is selected for support under this program, a statement of approval of the full dissertation committee is required before funding begins.

## IV. PURPOSE AND TERMS OF THE AWARD

This is a one-year, non-renewable award intended to provide $10,000 to $25,000 (total direct costs) for technical personnel support and supplies essential for the success of the proposed research. Applicants are encouraged to consider the whole

budget range delineated above. Dependent on favorable review and contingent on the availability of funds, the program expects to make 15-20 awards in Fiscal Year 1986.

V. APPLICATION AND REVIEW PROCEDURES

The format for preparing this shortened application is different from that used for regular research project grants. Therefore, before preparing an application, additional information and instructions must be obtained from one of the Program staff contacts listed below under **CONSULTATION WITH PROGRAM STAFF.** Applications must adhere to this format to be responsive and should be submitted on Form PHS 398, available at most institutional business offices or from the Division of Research Grants, NIH. A single yearly reply date of January 2 will be strictly enforced. An anticipated schedule for review and award is detailed below:

| Receipt Date | NIADDK Special Review Committee | NIADDK Advisory Council Review | Award |
|---|---|---|---|
| January 2, 1986 | March 1986 | May 1986 | July 1986 |

VI. REVIEW CRITERIA

Applications will be evaluated with respect to the following criteria: the scientific merit of the proposed project; the significance of a successful outcome to our understanding of the pathogenesis and treatment of inherited metabolic diseases; its characterization as innovative, high-risk or relevant to cystic fibrosis; the appropriateness or adequacy of methodology, including choice of experimental material; the investigator's background and training for carrying out the project; adequacy of the available facilities; and the adequacy of justifications presented for budget requests.

Innovative projects are defined as being unusually imaginative or representing a dramatically different approach to a problem. High risk projects are those for which success is highly uncertain but which, if successful, would constitute an important breakthrough.

VII. REPORTING REQUIREMENTS

If an award is made in response to a Small Grant application, a Final Progress Report, an Invention Statement and a Financial Status Report must be submitted within ninety days after the termination of the award. This final reporting requirement is the same as that for other types of research grants and is in accord with 42 CFR 52 and 45 CFR 74. This information will be especially helpful to the program in evaluating the usefulness of this Small Grant Award Mechanism.

VIII. CONSULTATION WITH PROGRAM STAFF

Prospective applicants are strongly encouraged to discuss their ideas with Program staff (see below) to determine whether they fit the definition and guidelines of this announcement. Applications which, in the opinion of staff, do not meet these objectives, scope and eligibility criteria will be returned without review.

For further information, such as application format and submission instructions, prospective applicants should contact:

For inherited metabolic diseases other than cystic fibrosis

Dr. Robert Katz
Director
Metabolic Diseases
Research Program, NIADDK
Room 607 - Westwood Bldg.
NIH, Bethesda, MD 20892
Phone: (301) 496-7997

or

Dr. Nancy Lamontagne
Assistant Director
Metabolic Diseases
Research Program, NIADDK
Room 607 - Westwood Bldg.
NIH, Bethesda, MD 20892
Phone: (301) 496-4980

For cystic fibrosis

Dr. Valerie Setlow
Director, Cystic Fibrosis
Program, NIADDK
Room 620B - Westwood Bldg.
NIH, Bethesda, MD 20892
Phone: (301) 496-7852

or

Dr. Judith Fradkin
Chief, Endocrine and Metabolic
Diseases Programs Branch, NIADDK
Room 626A - Westwood Bldg.
NIH, Bethesda, MD 20892
Phone: (301) 496-7791

## ANNOUNCEMENT

## AVAILABILITY OF REQUEST FOR APPLICATIONS: RFA 85-OD-02

## ACADEMIC RESEARCH ENHANCEMENT AWARD

**P.T. 34, 14; K.W. 0710030**

**NATIONAL INSTITUTES OF HEALTH**

Application Receipt Date: January 15, 1986

In its report accompanying the Fiscal Year 1985, appropriation for the National Institutes of Health (NIH) Congress called for an initiative to strengthen the research milieu of non-research-intensive, four-year colleges and universities which provide undergraduate training for a significant number of our nation's research scientists. In FY 85, the NIH made $5,000,000 available for this purpose and will be able to award over 75 "Academic Research Enhancement Awards" (AREAs). This award is designed to enhance the research environment of educational institutions that have not been traditional recipients of NIH research funds. The award is intended to support new research projects or expand ongoing research activities proposed by faculty members of these institutions in areas related to the health sciences.

The NIH is inviting grant applications for a second round of AREAs to be awarded in FY 86.

Institutions eligible for the AREA Program are defined as those that offer baccalaureate degrees in the sciences related to health, but did not receive an NIH Biomedical Research Support Grant (BRSG) in FY 1985. If in doubt about whether an institution has received a BRSG, contact the following office:

Office of Grants Inquiries
Westwood Building
National Institutes of Health
Bethesda, Maryland 20892

Investigators eligible for the Program are those who, at the time of award of an AREA grant, neither have active research grant support from NIH/ADAMHA (Alcohol, Drug Abuse, and Mental Health Administration) nor will be applying for competing continuation of such support. Applicants for AREAs are not eligible to submit a regular NIH or ADAMHA research grant application for essentially the same project.

Funding decisions will be based on the proposed research project's scientific merit and relevance to NIH programs, and the institution's contribution to the undergraduate preparation of doctoral-level health professionals. Among projects of essentially equivalent scientific merit and program relevance, preference will be given to those submitted by institutions that have granted baccalaureate degrees to 25 or more individuals who, during the period 1977-1984, obtained academic or professional doctoral degrees in the health related sciences.

AREAs are awarded on a competitive basis. Applicants may request support for up to $50,000 in direct costs (plus applicable indirect costs) for a period not to exceed 24 months. Although this award is non-renewable, it will enable qualified individual scientists within the eligible institutions to receive support for feasibility studies, pilot studies and other small-scale research projects preparatory to seeking more substantial funding from the regular NIH research grant programs.

Applications for this award will be accepted under the regular application submission procedures of the Division of Research Grants (DRG) of NIH. Grant applications must be prepared and submitted on PHS 398 grant application forms. An abbreviated format and simplified instructions will be provided for use in preparing these applications. The receipt date is January 15, 1986.

Those individuals and institutions meeting eligibility requirements and wishing to receive further information and/or application materials should write to:

AREA
Office of Grant Inquiries
Division of Research Grants
National Institutes of Health
Westwood Building - Room 449
Bethesda, Maryland 20892

## ANNOUNCEMENT

## PREVENTIVE CARDIOLOGY ACADEMIC AWARD

**P.T. 34; K.W. 0785025, 0745055**

**DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS**

**NATIONAL HEART, LUNG, AND BLOOD INSTITUTE**

Application Receipt Date: April 1, 1986

The Division of Epidemiology and Clinical Applications (DECA) of the National Heart, Lung, and Blood Institute (NHLBI) has initiated the Preventive Cardiology Academic Award (PCAA) to provide a stimulus for the development of a preventive cardiology curriculum in those schools of medicine and osteopathy that do not have one and to strengthen and improve the preventive cardiology curriculum in those schools that do. Each school of medicine or osteopathy in the United States and its possessions or territories is eligible to compete for one award for a project period that does not exceed five years. The number of awards made each year will depend upon the merit of the applications received and availability of funds.

For the purposes of the PCAA, the term preventive cardiology is used to define the area of cardiovascular medicine having a special concern with the development of knowledge and the application of knowledge directed at the prevention of heart and vascular diseases. This includes the area of primary prevention of cardiovascular diseases in infants, children, and adults who are at risk of developing such diseases and the reduction of preventable complications or disability in persons who have already developed cardiovascular disease.

This award is intended to:

Encourage the development of a high quality preventive cardiology curriculum in schools of medicine and osteopathy that will significantly increase the opportunities for students and house staff to learn both the principles and practice of preventive cardiology.

Develop promising faculty whose interest and training are in preventive cardiology teaching, research, and practice.

---

This program is described in the Catalog of Federal Domestic Assistance No. 13.837, Heart and Vascular Diseases. Awards will be made under the authority of the Public Health Service Act, Section 301 (42 USC 241) and administered under PHS grant policies and Federal Regulations, most specifically 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency Review.

Develop established faculty who have a major commitment to and possess educational skills for teaching preventive cardiology.

Facilitate interchange of educational ideas and methods applicable to teaching preventive cardiology among awardees and institutions.

Develop at the grantee institution the ability to strengthen continuously the improved preventive cardiology curriculum, with local funds, subsequent to the award.

Requests for copies of the PCAA Program Guidelines should be directed to:

Curt D. Furberg, M.D.
Associate Director
Clinical Applications and Prevention Program
Division of Epidemiology and Clinical Applications
National Heart, Lung, and Blood Institute
Federal Building - Room 6A-14
Bethesda, Maryland 20892

Telephone: (301) 496-1706

## ANNOUNCEMENT

## STUDIES ON FELINE RETROVIRUSES

**P.T. 34; K.W. 1002045, 1002008, 0785140, 0745040**

**NATIONAL CANCER INSTITUTE**

Initial Application Receipt Date: November 1, 1985

Subsequent Receipt Dates: February 1, June 1, October 1

I. INTRODUCTION

The Division of Cancer Etiology (DCE) of the National Cancer Institute (NCI) invites grant applications to perform investigator-initiated research on the biology and/or molecular biology of the retroviruses of the cat. The award will enable successful candidates to investigate a defined research problem in this area of programmatic interest to NCI for three to five years.

Among the retroviruses, the leukemia-inducing viruses of the cat (feline leukemia viruses, FeLV) are unique in many respects. First, they are responsible not only for malignant diseases, such as leukemia, lymphosarcoma, and other neoplastic conditions, but they also cause other serious diseases such as anemia, immunosuppression, and reproductive failure. More cats die of complications arising from the immunosuppression caused by FeLV than through tumor induction. In this respect, a parallel exists between FeLV and the recently discovered human retrovirus, human T-cell leukemia/lymphoma virus (HTLV), especially HTLV-III. The fact that FeLV has the potential to induce diverse disorders in the cat poses the question of whether differences in the induced diseases are a result of differences in the nature of the virus isolates. Differences between viral strains responsible for differences in the induced diseases in cats have not been elucidated and much research remains to be done in this area. Second, an examination of oncogene sequences in feline sarcoma viruses has revealed an abundance and diversity of oncogenes acquired through recombination with the cat genome, thus suggesting that the cat may be a reservoir of many different cellular oncogenes. Since oncogenes of different species appear to be similar and to be well conserved, the cat cellular oncogenes may have important implications for cancer in other species, including man. A third feature of the feline retroviruses, just beginning to be recognized, is the unexpected finding that certain leukemia inducing FeLV strains acquire, retain, and transduce the oncogene myc in a manner reminiscent of the avian myelocytomastosis virus, MC-29. This finding, previously unknown for a mammalian retrovirus, remains to be fully studied for its relevance in the etiology of the malignancies and the other diverse diseases attributed to FeLV.

---

This program is described in the Catalog of Federal Domestic Assistance 13.394, Cancer Detection and Diagnosis Research. Grants will be awarded under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended: 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

## II. OBJECTIVES AND SCOPE

The major emphasis of the program announcement is to encourage studies on the biology and molecular biology of feline leukemia virus. Examples of important areas of research emphasis (which are not all encompassing) are: (1) elucidate the mechanisms of feline retroviral cell transformation/oncogenesis, with attention to the newer knowledge of oncogene chromosomal translocations and other interactions; (2) explore the origin and significance of virus subgroups in feline leukemia virus-induced disease and immunity; and (3) to elucidate the pathogenesis of the disease(s), define feline hemopoietic and lymphoid cell populations in order to identify the target cells in malignant and immunosuppressive disorders. Additional studies that might be addressed are: (1) define the significance of subgroup C FeLV envelope component and the apparently protective antibodies against feline leukemia that it induces; (2) characterize myc-containing feline leukemia viruses and determine their role in feline leukemia; and (3) determine the etiology of virus negative cat tumors which generally appear under natural conditions in cats raised in an FeLV infected environment.

## III. MECHANISM OF SUPPORT

The mechanism of support for this program will be the grant-in-aid (traditional research grants - R01). All PHS and NIH policies governing regular research project grants, including cost sharing, will apply to applications received in response to this request.

## IV. APPLICATION AND REVIEW PROCEDURES

### A. Eligibility

Scientists affiliated with public or private profit and nonprofit institutions and other organizations such as universities, colleges, hospitals, and laboratories may apply.

### B. Method of Applying

Applications should be submitted on form PHS 398, which is available in the business or grants and contracts office at most academic and research institutions. On the face page of form PHS 398, indicate that the application was prepared in response to the Program Announcement entitled **"Studies on Feline Retroviruses."** The original and six copies of the application should be sent or delivered to:

Application Receipt
Division of Research Grants
National Institutes of Health
Westwood Building - Room 240
5333 Westbard Avenue
Bethesda, Maryland 20892

C. Deadlines

Applications will be accepted in accordance with the revised NIH receipt dates for new applications - February 1, June 1, and October 1. Applications submitted for the November 1 1985 date will be accepted and reviewed for the May 1985 Council review.

D. Assignment of Applications

Applications will be received by the NIH Division of Research Grants (DRG), referred to an appropriate Study Section for scientific merit review, and assigned to individual Institutes for possible funding. Referral decisions will be governed by normal programmatic considerations as specified in the Referral Guidelines of the NIH DRG.

E. Review Procedures

Applications in response to this solicitation will be reviewed on a nation-wide basis in competition with other research grant applications, and in accord with the usual NIH peer review procedures. Applications will first be reviewed for scientific and technical merit by a review group composed mostly of non-Federal scientific consultants (Study Section), and then by the National Advisory Council of the appropriate Institute(s). The review criteria customarily employed by the NIH for regular research grant applications will prevail.

V. INQUIRIES

Inquiries may be directed to:

Padman S. Sarma, D.V.M., Ph.D.
Biological Carcinogenesis Branch
Division of Cancer Etiology
National Cancer Institute
Landow Building - Room 9A22
Bethesda, Maryland 20892
(301) 496-9734

Inquiries concerning this announcement are encouraged. To facilitate the administration of this program announcement, communication of your intention to apply is requested. This does not require a formal letter of intent by a specified deadline, and does not imply review or approval of the idea by the Biological Carcinogenesis Branch, prior to the submission of an application. The Branch would appreciate receiving information about your proposal, includ ing the name of the Principal Investigator, Institution, estimated costs, listing of key professional personnel, and abstract of the research plan.

# ANNOUNCEMENT

## THE NCI OUTSTANDING INVESTIGATOR GRANT

**P.T. 34; K.W. 0715035, 0710030**

**NATIONAL CANCER INSTITUTE**

Application Receipt Date: May 15

I. SUMMARY AND PURPOSE

The National Cancer Institute (NCI) will continue to accept applications for the Outstanding Investigator Grant (OIG), the purpose of which is to provide long-term support to experienced investigators with outstanding records of research productivity. The OIG is intended to encourage investigators to embark on projects of unusual potential in cancer research. Emphasis will be placed on evidence of recent substantive contributions, i.e., seminal ideas and innovative approaches to resistant problems.

II. ELIGIBILITY

Applications may be made by domestic institutions on behalf of investigators who have recently demonstrated outstanding research productivity for at least five years. There are no age restrictions. Only United States citizens, nationals or permanent residents may be presented as candidates for this grant.

III. PROVISIONS OF THE GRANT

The OIG is nontransferable and is awarded for a maximum period of seven years. The grant is not a lifetime award but is renewable. Application for competitive renewal should be submitted at the end of the fifth year according to the guidelines for the initial award.

The actual dollar award will reflect specifically the investigator's current and projected research needs evaluated by the Initial Reviewers, and reviewed by the Executive Committee, NCI. The award will provide that fraction of the investigator's salary that approximates the total proportion of salary awarded through current grants, but is not to exceed 75%. This limit may be waived under exceptional conditions such as evidence of institutional provision of unusual levels of support of other types.

Funds will be provided for the support of technical staff, research staff and graduate students, but not for other academic faculty or institute equivalents. Salaries of other principal investigators may not be included. Other expenses, as would be included in individual project grants, are legitimate costs. It is required that the OIG Principal Investigator will commit at least 75% of his/her time and effort to the research supported by this instrument.

Candidates for this award may concurrently apply for additional NIH research grant or research contract support for the balance of his/her time and effort, provided the requirement that the candidate institution provide 25% salary support has been waived. Renegotiation of all concurrent NIH funds upon acceptance of this grant is required.

Candidates for this award may apply concurrently for training grants, construction grants and capital equipment grants.

## IV. REVIEW PROCEDURES AND CRITERIA

### A. Review Method

Applications submitted in response to this Announcement will be assigned to an appropriate subset of a nationwide panel of recognized cancer investigators for review. The summary statements from this Initial Review Group will be submitted by the Executive Secretary, DEA, NCI, to the NCI Executive Committee to prepare its funding recommendations for the National Cancer Advisory Board (NCAB). The NCAB will recommend awards to the Director, NCI, for final action.

### B. Review Criteria

Reviewers will consider the following factors in evaluating the scientific merit of each response to this Program Announcement:

1. What has been the impact of the applicant's work on the field of biomedical research?

    a. Is his/her research cited often and as incentives for other's research efforts?

    b. Has the applicant developed new experimental approaches crucial to the progress of his/her area of research?

    c. Has he/she contributed to the collection of important reliable data?

    d. In what way is the applicant's work seminal in nature?

    e. Has the applicant productively exploited his/her own breakthroughs and/or those of others?

    f. Has the applicant demonstrated imagination, energy, and sensitivity to the potential of serendipitous findings?

2. What will be the significance of the investigator's continued work in the field described above?

    a. Does the proposed work break new ground or continue previous work?

    b. Are the questions posed of significant interest and importance to cancer research?

c. Will this work provide impetus for others working in related areas?

3. Is there a strong likelihood that the investigator will continue at the frontiers of research?

C. Evaluation of the capabilities of the applicant

1. Comment on the way in which the applicant has achieved his/her present stature in the field. Speak both to the individual accomplishments and to collaborative interactions.

2. Has the applicant made significant contributions in the areas of teaching and research training and/or clinical research? Comment on the applicant's communicative, pedagogic, and organization skills.

D. Resources and Environment

Will the applicant have adequate administrative support as indicated by institutional commitment of facilities and other resources, as appropriate?

V. HOW TO APPLY

- Letters of Intent are no longer requested.

- Application for this award should be made on form PHS 398 (Rev. 5/82) in accordance with instructions in this Announcement. These applications are available in the business or contracts offices at most academic or research institutions, or from:

Division of Research Grants
National Cancer Institute
Bethesda, Maryland 20205

- The title **"NCI OUTSTANDING INVESTIGATOR GRANT"** should be typed in section 2 on the first page of the application.

- Beginning in 1986, the date for receipt of applications will be May 15 of each year. Applications received by July 15, 1985, in accordance with previously published guidelines, will be processed for review at the earliest possible meeting of the NCAB.

- The research proposal must be cancer-related as defined by the Division of Research Grants (DRG) grant application referral guidelines. Its prose portion should not exceed ten typewritten single spaced pages. Applications must be accompanied by a curriculum vita and bibliography. Abbreviated curriculam vitae of all persons listed on the personnel page should be included. No more than five publications may be submitted.

- A letter indicating clear and continuing institutional commitment to the applicant must be submitted. This commitment should include salary support at least to the current level, but may not be less than 25 percent. This

minimum salary requirement may be waived under exceptional provision of unusual levels of support of other types. Adequate physical facilities, staff and administrative resources appropriate to the role of the OIG awardee must be provided. This should be a separate page which precedes the budget page.

- The applicant investigator and his/her institution must present a workable plan for phase-out of the applicant's current research support and conversion of staff and facilities to support by the OIG. This must be submitted as an appendix to the application.

- The original and six copies of the application should be submitted to DRG, NIH, as directed in the instructions of the grant application.

## VI. INQUIRIES

Please direct inquiries for further information on application development to:

Mrs. Barbara S. Bynum
Director
Division of Extramural Activities
National Cancer Institute
Building 31 - Room 10A03
Bethesda, Maryland 20892

Telephone: (301) 496-5147

## ANNOUNCEMENT

**AVAILABILITY OF REVISED PROGRAM ANNOUNCEMENT***

**MH-85-07**

**RESEARCH SCIENTIST DEVELOPMENT AND RESEARCH SCIENTIST AWARD**

**P.T. 34; K.W. 0404003, 0404009, 0715095**

**ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION**

**NATIONAL INSTITUTE ON DRUG ABUSE**

**NATIONAL INSTITUTE OF MENTAL HEALTH**

The Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) announces the availability of a revised program announcement for the Research Scientist Development Award (RSDA) and the Research Scientist Award (RSA) grants programs which are designed to foster the development of outstanding scientists and to enable them to expand their potential for making important contributions to the fields of alcoholism, drug abuse, and mental health research. This is accomplished by mechanisms which enable exceptionally talented investigators to engage in research on an essentially full-time, long-term basis. Awards are made to institutions on behalf of specific outstanding individuals. The awards are intended to enhance the individual awardee's skills and dedication to these areas of research. They are also intended to assist recipient institutions in maintaining and expanding existing research programs or establishing new ones for studies concerning alcohol, drug abuse, or mental health.

I. TYPES OF AWARDS

Two types of awards are available: the RSDA at Levels I and II, and the RSA. RSDA (Level I) is designed to support individuals with exceptional research potential who need further supervised research experience. Applicants may be scientists or clinicians with limited research experience, or scientists prepared in one discipline who want supervised experience in another.

* This revised RSDA/RSA announcement is being issued primarily to provide updated administrative and program guidance to current and potential awardees.

This program is described in the Catalog of Federal Domestic Assistance Nos. 13.271, Alcoholism Research Scientist Development and Research Scientist Awards; 13.277, Drug Abuse Research Scientist Development and Research Scientist Awards; and 13.281, Mental Health Research Scientist Development and Research Scientist Awards. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

RSDA (Level II) is geared to support persons capable of designing and conducting original research but who need additional research experience in order to reach their potential as outstanding scientists. An applicant for this award must either have successfully completed a Level I award or be able to demonstrate significant research skills by a record of independent research and publication.

The RSA is designed to support outstanding senior investigators in order to enable them to spend essentially full time in research. An applicant for this award need not have received prior developmental support from ADAMHA (e.g., an RSDA).

II. ELIGIBILITY

Public, non-profit, private, or for-profit organizations and institutions engaging in health-related research and located in the United States or its territories may apply for grant support under the RSDA and RSA programs. Applications are encouraged from institutions with research programs in alcohol, drug abuse, and mental health, e.g., from all departments within medical and graduate schools, from research institutions, and from other organizations such as hospitals and clinics with research capabilities.

Individual candidates for the RSDA are required to have a minimum of three years postdoctoral experience. Awards will be made to those individuals who can best demonstrate the benefits provided by allowing them release time to pursue essentially full-time research. This can be accomplished by relieving them from reliance on support derived primarily from research grants, contracts, or similar sources of relatively short-term duration; changing the terms of their current position from a major involvement in nonresearch activities to essentially full-time research; and enabling them to accept a new position in research for which institutional funds are not available.

Candidates for RSDA and RSA awards must be U.S. citizens or have been lawfully admitted to the United States for permanent residence at the time of the award.

Scientists who hold a position with firm salary support for essentially full-time research are not eligible under these programs. ADAMHA is interested in applications from all well-qualified individuals; women and minority candidates in particular are encouraged to apply.

III. PROGRAM CONTACTS

Current awardees and potential applicants interested in obtaining a copy of the revised announcement or more information on these programs should contact:

Lois Chatham, Ph.D., Director
Extramural Research, NIAAA
Parklawn Building - Room 14C-10
Telephone: 301 - 443-2530

Jean Paul Smith, Ph.D.
Deputy Associate Director of Science, NIDA
Parklawn Building - Room 10-05
Telephone: 301 - 443-6480

Ellen Simon Stover, Ph.D.
Chief, Research Resources Branch
Division of Extramural Research
Programs, NIMH
Parklawn Building - Room 10-104
Telephone: 301 - 443-4337

The mailing address for all of the above is: 5600 Fishers Lane, Rockville, Maryland 20857.

## ANNOUNCEMENT

## AVAILABILITY OF NEW INVESTIGATOR AWARDS

**P.T. 34; K.W. 0404003, 0404009, 0715095, 0404000, 0785055, 0760050,, 0415000**

**NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM**

**ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION**

I. INTRODUCTION AND PURPOSE

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) encourages basic and applied research on all biomedical and psychosocial aspects of alcoholism and alcohol-related health problems. This announcement solicits applications for New Investigator Research Awards (NIRAs). The NIRA program is designed to help new investigators develop their research interests and capabilities in alcohol-related biomedical and psychosocial research. Support of these projects is expected to aid researchers in making the transition from training status to independent investigator. In addition, this program seeks to attract scientists with more than five years of research experience in another field, provided they have not been a principal investigator on an NIAAA-supported project or published extensively in the alcohol research field. NIAAA is interested in applications from all well-qualified individuals. Women and minority persons, particular, are encouraged to apply.

It is anticipated that up to 15 to 20 New Investigator Research Awards will be funded in FY 1986, subject to final congressional action on the FY 1986 appropriation for alcohol-related research. Applications should be received by November 1, 1985, to assure consideration for funding in FY 1986; however, applications submitted for subsequent deadline dates will be reviewed and considered for funding in accordance with the established schedule.

II. AREAS OF INTEREST

The NIAAA invites applications for research grants on biomedical, behavioral, clinical, sociocultural and epidemiological factors associated with the use or abuse of alcohol, the prevention and treatment of alcohol-related health problems, and the consequences of these health problems. Some areas of interest are:

Biomedical and genetic research, such as the study of alcohol metabolism and the genetic variability of metabolic pathways and susceptibility to alcoholism, and the development of animal models.

Epidemiologic research, such as studies of drinking patterns and derived health consequences among specific target populations (age groups, gender, ethnic, occupational).

Neuropharmacological research, such as the cellular and molecular basis of alcohol intoxication, the role of the nervous system in tolerance and dependence, the effects of alcohol on neurotransmitters and neuroendocrine systems, the study of alcohol and drug interactions, and membrane structure and function.

Pathology-related research on the nature of alcohol-associated diseases, the relationship between alcoholism and other behavioral disorders, and the teratogenic effect of alcohol on pregnancy outcome.

Prevention research, such as the study of preventive interventions to reduce the incidence of alcohol-related disorders and alcoholism, and to promote risk-reducing behaviors; the development of methods for the detection of high-risk precursors; and the influence of law and policy on the incidence and prevalence of alcohol problems.

Psychosocial research, such as the cognitive effects of alcohol abuse, the social and cultural differences in alcohol consumption, and the role of drinking in relation to accidents, violence, and crime.

Treatment and occupational research, such as the assessment of treatment outcome, the study of treatment efficacy, and the identification of factors that may affect the willingness of individuals to enter into treatment programs, including the study of early identification and intervention in the workplace. Of special concern are the studies that match characteristics of patients/clients (e.g., age, gender, personality traits, ethnicity) with specific treatment modalities.

In each of the above areas, NIAAA is particularly interested in projects which focus on alcohol-related problems of women, adolescents and youth, the elderly and minority ethnic groups.

## III. APPLICATION PROCEDURES AND ELIGIBILITY

A NIRA award is primarily intended for a new investigator who has less than five years of research experience after completion of formal professional training, and who has not been a principal investigator on a NIAAA research grant. A new investigator with previous support under either a fellowship or training grant is eligible to apply. The principal investigator (applicant) must have completed his or her formal training and ordinarily must have a doctoral degree or its equivalent.

The NIAAA also allows investigators with more than five years of research experience in another field to apply for a NIRA providing they have not been a principal investigator on a NIAAA research project, or have not published extensively (five or more journal publications) in the alcohol research field.

A copy of the full NIRA program announcement may be obtained by writing to the National Clearinghouse for Alcohol Information, P.O. Box 2345, Rockville, Maryland 20852. Further information on program requirements and application procedures can also be obtained from:

Dr. Helen Chao
Chief, Biomedical Research Branch
or
Dr. Ernestine Vanderveen
Chief, Clinical and Psychosocial Research Branch
Parklawn Building - Room 14C-17
5600 Fishers Lane
Rockville, Maryland 20857

Telephone: (301) 443-4223

☆ U. S. GOVERNMENT PRINTING OFFICE : 1985 461-312/20007

## NOTICE

## RESPONSE REQUIRED

It is the intention of NIH to combine the NIH Guide for Grants and Contracts with the Guide Supplements into a weekly publication to be mailed to all persons on the NIH mailing list. If you wish to continue receiving any information about Grants or Contracts, return this page within 30 days (60 days for foreign correspondents). Failure to do so will automatically remove your name from our mailing list.

### PLEASE FOLLOW THESE INSTRUCTIONS

1. Correct any inaccuracies that appear in your address.

2. Remove the mailing label and tape it in the designated area below. If you are receiving duplicate mailings, please include all labels.

3. If you are interested in receiving special mailings in the following categories, please check the appropriate box(es).

   a. ☐ Programs concerned with minority health and participation of minorities in research.

   b. ☐ Programs directed at small business /disadvantaged business (other than Small Business Innovation Research).

4. Remove this page and place it in an envelope.

5. Address to:

   Institutional Liaison Office
   National Institutes of Health
   Building 1 - Room 115
   Bethesda, Maryland 20892

6. Stamp and mail.

Affix label(s) here